Immuron Ltd (IMRN)
NASDAQ:IMRN
IMRN Stock Chart & Stats
$0.82
-$0.03(-1.20%)
At close: 4:00 PM EST
$0.82
-$0.03(-1.20%)
Day’s Range― - ―
52-Week Range$0.68 - $2.39
Previous CloseN/A
Volume5.19K
Average Volume (3M)75.95K
Market Cap
$6.24M
Enterprise Value-$3.03M
Total Cash (Recent Filing)$9.99M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.02
Next Earnings
Aug 28, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding8,166,340
10 Day Avg. Volume112,552
30 Day Avg. Volume75,952
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.90
Price to Sales (P/S)2.09
P/FCF Ratio-2.49
Enterprise Value/Market Cap-0.49
Enterprise Value/Revenue-0.34
Enterprise Value/Gross Profit-0.53
Enterprise Value/Ebitda0.46
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.01
Revenue Forecast (FY)$6.31M
Bulls Say, Bears Say
Bulls Say
Low LeverageA very low debt-to-equity ratio provides durable financial flexibility by minimizing interest burden and default risk. This conservative capital structure preserves balance-sheet optionality to fund commercialization, R&D or targeted marketing without large fixed financing costs while losses are addressed.
High Gross MarginsSustained gross margins near 65% indicate attractive unit economics for colostrum-based products. Strong product-level margins create scope to absorb SG&A and R&D, and enable scalable profitability as distribution and volumes rise, supporting long-term margin recovery if operating costs are controlled.
Growing OTC Sales And New Product LaunchConsistent Travelan sales growth, stronger Q2 momentum, expanded pharmacy ranging and a national ProIBS launch broaden revenue channels and distribution. These durable commercial gains and multi-market traction increase the likelihood of steady OTC cash generation and scale benefits over the next several quarters.
Bears Say
Declining Revenue & Negative Cash FlowAn ongoing top-line decline and negative operating/free cash flow are structural constraints that limit reinvestment and force reliance on external funding. Persistent cash deficits reduce runway for marketing, distribution expansion and clinical development absent sustained OTC growth or material funding events.
Deeply Negative Profitability And ROEConsistent deeply negative net margins and a negative return on equity show the company is not generating returns from invested capital. This undermines investor confidence, raises the cost of capital and impedes long-term value creation until operating profitability is achieved.
Dependence On Equity FundingRatification of prior share issues highlights recurring reliance on equity financing to support operations and pipeline development. Structural dependence on dilutive funding creates ongoing shareholder dilution risk and constrains strategic choices if internal cash generation remains weak.
Immuron News
IMRN FAQ
What was Immuron Ltd’s price range in the past 12 months?
Immuron Ltd lowest stock price was $0.68 and its highest was $2.39 in the past 12 months.
What is Immuron Ltd’s market cap?
Immuron Ltd’s market cap is $6.24M.
When is Immuron Ltd’s upcoming earnings report date?
Immuron Ltd’s upcoming earnings report date is Aug 28, 2026 which is in 135 days.
How were Immuron Ltd’s earnings last quarter?
Immuron Ltd released its earnings results on Feb 25, 2026. The company reported -$0.199 earnings per share for the quarter, missing the consensus estimate of -$0.007 by -$0.192.
Is Immuron Ltd overvalued?
According to Wall Street analysts Immuron Ltd’s price is currently Overvalued.
Does Immuron Ltd pay dividends?
Immuron Ltd does not currently pay dividends.
What is Immuron Ltd’s EPS estimate?
Immuron Ltd’s EPS estimate is >-0.01.
How many shares outstanding does Immuron Ltd have?
Immuron Ltd has 8,166,340 shares outstanding.
What happened to Immuron Ltd’s price movement after its last earnings report?
Immuron Ltd reported an EPS of -$0.199 in its last earnings report, missing expectations of -$0.007. Following the earnings report the stock price went up 17.103%.
Which hedge fund is a major shareholder of Immuron Ltd?
Currently, no hedge funds are holding shares in IMRN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Immuron Ltd
Immuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and reduce the symptoms of minor gastro-intestinal disorders, as well as for dietary supplement for digestive tract protection; and Protectyn, an immune supplement to maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III clinical trials to reduce the risk of contracting travelers' diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in clinical development stage focuses on treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and ETEC infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is based in Carlton, Australia.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
0.02% Other Institutional Investors
99.98% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---